---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-127609"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:40:47.839991+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma raises $75M via private placement with TCGX for telitacicept development

## Summary
- Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
- Closing expected March 30, 2026; no placement agent used.
- Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.
- TCGX managing partner expresses confidence in telitacicept's differentiated profile.
- Registration rights agreement to file resale registration statement within 30 days.

## SEC filing metadata
- accession: 0001193125-26-127609
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/vor-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-127609
- JSON: https://secwatch.observer/filing/0001193125-26-127609.json
- Plain text: https://secwatch.observer/filing/0001193125-26-127609.txt

## Key facts
- Equity Issuances
  Vor Biopharma Inc. issued 5,338,078 shares of common stock to TCGX for $14.05 per share.
  - Security: common stock
  - Shares: 5,338,078 shares
  - Purchaser: TCGX
  - Consideration: $14.05 per share
  source text: entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm
- Material Agreements
  Vor Biopharma Inc. entered into Securities Purchase Agreement with entities affiliated with TCGX valued at approximately $75.0 million (effective 2026-03-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: entities affiliated with TCGX
  - Value: approximately $75.0 million
  - Effective: 2026-03-26
  source text: On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.